- Two-year data from the Phase 1/2 ZUMA-1 study evaluating Gilead Sciences' (NASDAQ:GILD) Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma showed a sustained treatment effect. The results were presented at ASH in San Diego.
- With median follow-up of 27.1 months and a minimum of 24 months after a single infusion of Yescarta, 39% of patients maintained their responses. The best objective response via investigator assessment was 83% (n=84/101) at year 2, including 58% (n=59/101) with complete responses.
- 93% of patients who responded at month 12 continued to show responses at month 24. Median duration of response was 11.1 months. Median duration of complete response and median overall survival had not been reached.
- On the safety front, the incidences of serious/life-threatening cytokine release syndrome (CRS) and neurological events were 11% and 32%, respectively, at year 2, but were generally reversible. Four patients developed new serious adverse events since the previous data cutoff on August 11, 2017, but none were related to Yescarta.
- #ASH18
- Now read: The Oil Turn, Soaring Goose, And Value Traps
Original article